The Food and Drugs Authority (FDA) have approved a herbal medicine scientifcally called Cryptolepis sanguinolenta and locally known as Nibima for clinical trials on COVID-19.
The FDA indicated that the trials will be conducted at two treatment centres for the time being.
The FDA in press release on Monday, February 1, 2021, signed by Chief Executive Officer of FDA, Mrs. Delese A.A. Darko said the approval was granted in January 2021.
The press release also revealed that the herbal medicine was submitted by the School of Public Health at the Kwame Nkrumah University of Science and Technology, (KNUST). Before it was approved, the school submitted a clinical trial application in September 2020.
“The Food and Drugs Authority (FDA), The National Medicine Regulatory Agency (NMRA) in Ghana, has approved a herbal medicine, Cryptolepis sanguinolenta, locally known as Nibima for clinical trials in January 2021.”
“In the search for a treatment for the ongoing COVID-19 pandemic, researchers from the School of Public Health at the Kwame Nkrumah University of Science and Technology, (KNUST), submitted a clinical trial application in September 2020 to assess the safety and efficacy of Cryptolepis sanguinolenta as a potential treatment for COVID-19. This follows results from laboratory studies conducted by the KNUST research team which points in the direction of possible clinical benefits.”
“The FDA after a detailed assessment of the application gave the requisite regulatory authority for the conduct of the trial as per the mandate outlined under Part 8 (Section 150-166) of the Public Health Act 2012 (Act 851), which gives the Authority the legal mandate to regulate clinical trials of drugs, herbal medicinal products, cosmetics or medical devices. The trial will be at two sites.”
Below is the full press statement from FDA